In the meanwhile, the feasibility of targeting Ca2+ channels has already been highlighted by clinical experience of voltage gated Ca2+ channel blockers for the treatment of hypertension, and also by the viable phenotype of TRPM8−/− mice [40]. This evidence concerns the gene TRPM8 and hypertensive disorder.